KH

Kate Haviland

Things Kate Says on Podcasts

Where to Find Them

Kate Haviland has been a guest on Biotech Hangout and BiotechTV - News .

Recently: “Episode 203 - November 13, 2026” on Biotech Hangout (November 2026); “Benchtalk 2025: Kate Haviland discusses the $9B+ acquisition of Blueprint by Sanofi, being chair of Fulcrum, her thoughts on M&A, and what is interesting in biotech today” on BiotechTV - News (October 2025).

What They Said

“If you walk into one of those and sit down in the postage stamp sized break room with the physician who has 15 minutes to come in, it becomes very, very clear why these things have a hard time getting traction. These physicians are overwhelmed. The waiting room is full of incredibly sick patients with numerous different types of cancers. And so you're trying to get them to pull a needle out of a haystack, even though your drug has an 80% response rate.” — Kate Haviland, Biotech Hangout

Asked why community oncologists don't adopt new targeted drugs even when a patient's mutation is on record, former biotech CEO Kate Haviland describes visiting a community clinic. Adoption fails on time and practice economics, not data.

Biotech Hangout · 2026-11-13 Permalink → Listen →
Biotech Hangout Around 54:01 into the episode
Kate Haviland

…of friction matter a lot. And I think that example in ret-driven lung cancer is a really great example where the last mile, the data on those drugs is amazing. Patients who are on them do extremely well. And they never lived up to what many very smart people thought the opportunity was going to be.

Yaron Werber

…They might not be aware that they have it in the medical record. And in many cases, we're talking about things that are very rare. And physicians at that point just don't have the time to remember that for Ross One, you should be giving this and not Chris Atney Broio. Or what's the challenge there?

Kate Haviland

Yeah, I mean, I think, you know, I'll never forget kind of walking into a community on colleague oncology clinic in a major in a major metropolitan center in the United States. And if you've never been in one, it's hard to understand why these like incredibly innovative new drugs with these incredible data sets don't get adopted. If you walk into one of those and sit down in the postage size stamped or poached stamp sized break room that has a refrigerator and you just sit in these like full bag chairs with the physician who has 15 minutes to come in, you start, it becomes very, very clear why these things have a hard time getting traction, right? These physicians are overwhelmed. The waiting room is full of incredibly sick patients with numerous different types of cancers, right? And so you're trying to get them to pull a needle of a haystack, even though your drug has an 80% response rate, right? And I think that's the reality that many don't, we don't talk about, we don't see that it's, it does take a long time. I think what's what's really helpful in some of these moments is getting to these big group practices, right? Getting some of this into their electronic pathways and their EMR systems, where you take some of the need to know…

Yaron Werber

You know, we hosted at ESMO a lung, a, I'm sorry, in a head and neck lunch with two real experts and talking about all the nuances of the drugs in development. And at some point, they all literally set time out. You guys in the audience know this data in and out better than 90% of the community…

Kate Haviland

Yeah. And, you know, and every tumor type is different, but most, you know, in many, much of oncology, 70% of patients are treated in the community. And often, you know, the patients who then make their way eventually to academic centers are later lying, right? So they've already seen multiple…

Eric Schmidt

Well, fascinating discussion. I know we went a little bit long with that topic, but Kate Haviland for pulling back the curtain a little bit and letting us see a little bit more of the inside scoop behind what's happening at companies during these very sophisticated drug launches. We only have a…

Speaker names come from our own diarization. The position is estimated from where the line sits in the episode.

Collections They Appear In